APOQUEL 3.6 mg

• Innovative drug, unique in its kind, for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs. Oclacitinib is a selective inhibitor of Janus kinase (JAK) enzymes.
• It can inhibit the function of several cytokines dependent on JAK enzyme activity.
• For Oclacitinib, the target cytokines are those cytokines that are pro-inflammatory or have a role in the allergic/pruritic response.

Presentations: 20 tab

Code: ACOM-00691